🟢 IBRX is trading 5% up today ahead of key FDA workshop for Anktiva expansion

IBRX is trading 5% up at $8.37 in pre-market ahead of a pivotal FDA workshop for its lead therapy Anktiva, bouncing from last Friday’s $7.97 close after a choppy week.

• The May 18 FDA workshop will focus on expanding ImmunityBio’s lead therapy into additional bladder cancer indications.
• Sentiment is further supported by optimism regarding the company's recent BCG partnership and broader commercialization strategy.